MOTS-c: Endogenous Biology Is Not Treatment Evidence

MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. It is a 16-amino-acid peptide encoded within a short open reading frame associated with mitochondrial 12S rRNA. ^{[3, 8]}

Endogenous MOTS-c is produced and measured within biology. An administered synthetic MOTS-c product creates a different question involving identity, route, exposure, metabolism, immune response, and clinical effect. ^{[8, 3]}

MOTS-c free base and MOTS-c acetate are different active pharmaceutical ingredients. FDA found the nomination ambiguous about which form was intended and evaluated both separately. ^{[3, 2]}

MOTS-c is a common name rather than a United States Adopted Name. FDA reported inconsistent naming and identifiers in the nomination and marketplace, which can obscure which form a certificate, product, or claim concerns. ^[3]

The foundational work linked MOTS-c with cellular metabolic pathways, skeletal-muscle signaling, insulin sensitivity, and AMPK-associated biology. Those findings generated a plausible research program rather than a licensed treatment claim. ^[8]

A later study found that exercise was associated with changes in endogenous MOTS-c in human muscle and circulation, while administered-MOTS-c performance and age-related findings came from cells and mice. That combination is scientifically interesting but easy to overread. ^[9]

MOTS-c has been promoted for insulin resistance, obesity, osteoporosis, vascular calcification, muscle/fat metabolism, longevity, weight loss, energy regulation, and physical performance. FDA found no administered-human clinical evidence establishing those uses. ^[3]

“Longevity” is especially demanding evidence-wise: a change in a pathway, exercise biomarker, or old mouse's treadmill result is not evidence that an administered product extends human life or healthspan. ^{[9, 3]}

In the human portion of a 2021 study, ten young men completed exercise on a stationary bicycle while researchers measured endogenous MOTS-c in skeletal muscle and blood. No participant was given MOTS-c. ^[9]

That observation is not a treatment trial. It can support the idea that endogenous MOTS-c responds to exercise, but it cannot show that injecting or otherwise administering synthetic MOTS-c improves performance, metabolism, aging, or disease outcomes. ^{[9, 3]}

FDA identified no clinical studies or human exposure data for MOTS-c by any route and no clinical pharmacokinetic study. It likewise found no administered-human study supporting the nominated uses. ^[3]

Detecting MOTS-c in human plasma or observing an exercise-associated change does not identify a safe administered exposure, a therapeutic window, a clinical endpoint, or a benefit–risk balance. ^{[8, 9, 3]}

The 2015 paper reported metabolic effects in cultured cells and mice, including results in mouse models of diet-related obesity and insulin resistance. Those are preclinical intervention findings, not human treatment outcomes. ^[8]

The 2021 paper reported physical-performance and age-related results after MOTS-c treatment in young, middle-aged, and old mice. The human component measured endogenous responses to exercise; it did not reproduce the mouse intervention in people. ^[9]

FDA noted that the molecular targets underlying MOTS-c's reported effects remain uncertain and that it is difficult to predict which organs may be affected. Mechanistic incompleteness matters when considering both benefit and unintended effects. ^[3]

Human translation would require a defined material, exposure and metabolism data, nonclinical toxicology, and controlled clinical studies measuring indication-specific outcomes. The existing cell and mouse findings do not complete those steps. ^{[3, 7]}

An in-vitro experiment found that MOTS-c was rapidly hydrolyzed in human blood. FDA said it remains unknown whether administration to people could generate pharmacologically active concentrations over time; blood in a laboratory tube is not a human pharmacokinetic study. ^[3]

FDA did not identify acute or other nonclinical toxicology studies sufficient to inform potential clinical use, nor human clinical safety data. Potential human safety risks are therefore unknown. ^[3]

FDA's surveillance searches retrieved no adverse-event reports, but many section 503A compounders do not routinely report adverse events to FDA. No reports in that setting cannot be interpreted as no adverse effects. ^[3]

FDA identified potential immunogenicity concerns for an injected peptide, which may be amplified by aggregation and peptide-related impurities. It found no clinical studies assessing immune responses or aggregation for MOTS-c-related substances. ^{[3, 6]}

For a proposed injectable product, identity, sterility, bacterial endotoxin, particulates, potency, impurities, aggregation, solubility, and microbiological quality are safety-critical. FDA found important gaps in those controls for both evaluated forms. ^{[3, 4]}

The MOTS-c nomination was withdrawn and was ambiguous about whether it covered free base or acetate. FDA evaluated both substances on its own initiative. ^[3]

The nomination named insulin resistance, obesity, osteoporosis, vascular calcification, muscle/fat metabolism, and longevity. FDA said the nomination lacked sufficient information for those uses and identified no relevant clinical administration studies. ^[3]

The July 2026 proceeding addressed possible placement on the 503A Bulks List. It was a compounding assessment, not an FDA approval review of a finished MOTS-c drug. ^{[3, 2]}

FDA staff concluded that characterization gaps, unknown compounding history, missing human safety and effectiveness data, and inadequate nonclinical safety information weighed against adding both forms to the 503A Bulks List. ^[3]

The advisory committee provides nonbinding advice to FDA. Its proceeding is not FDA approval, while a recommendation against list placement does not mean the peptide is banned in every legal or research context. ^{[5, 1]}

FDA's current compounding-risk page includes MOTS-c and highlights missing human exposure, immunogenicity, aggregation, and impurity concerns. The page is a risk-focused regulatory summary, not evidence that every possible harm has been quantified. ^[4]

Did a study measure the body's endogenous MOTS-c, administer synthetic MOTS-c to cells or animals, or administer a defined product to humans? Those designs answer different questions. ^{[8, 9, 3]}

Is the claim about a pathway, a biomarker, mouse performance, human symptoms, disease outcomes, or lifespan—and does the cited evidence actually measure that endpoint in the relevant population? ^{[9, 3]}

Which form and finished product are being discussed, and what evidence addresses identity, purity, sterility, bacterial endotoxin, aggregation, immune risk, human exposure, and adverse-event detection? ^{[3, 6]}